News

News Subscription

Sep 05. 2014
Extensive data presented on Basilea's anti-infectives isavuconazole, ceftobiprole and BAL30072 at ICAAC
Read more
Download
Aug 21. 2014
European Medicines Agency accepts Basilea's isavuconazole Marketing Authorization Application for review
Read more
Download
Aug 18. 2014
Basilea appoints Chief Commercial Officer
Read more
Download
Aug 14. 2014
Basilea reports 2014 half-year financials - ceftobiprole launch in Germany planned for second half of 2014
Read more
Download
Jul 21. 2014
Basilea to launch Zevtera®/Mabelio® (ceftobiprole medocaril) in Europe through a commercial services provider
Read more
Download
Jul 17. 2014
Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections
Read more
Download
Jul 17. 2014
Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis
Read more
Download
Jul 14. 2014
Basilea reports that isavuconazole receives orphan drug designations in Europe for the treatment of invasive mold infections
Read more
Download
Jul 10. 2014
Basilea's partner Astellas submits isavuconazole U.S. NDA for the treatment of invasive aspergillosis and invasive mucormycosis
Read more
Download
Jun 26. 2014
Basilea announces start of phase 2a study with oncology drug candidate BAL101553
Read more
Download